Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Praxis Precision Medicines, Inc.

Get SEC filing alerts via email and in your feed for Praxis Precision Medicines, Inc.

PRAX

Praxis Precision Medicines, Inc.

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines is a biopharmaceutical company focused on developing therapies for central nervous system disorders, particularly epilepsy and movement disorders. Utilizing genetic insights, its platforms create targeted small molecules and antisense oligonucleotides. The company advances precision medicines through clinical trials, leveraging collaborations and proprietary technologies to address unmet needs in neurological conditions with high patient burden.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Praxis Precision Medicines, Inc.

1
1
Praxis Precision Medicines, Inc. Praxis Precision Medicines Reports $92.6 Million Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Praxis Precision Medicines, Inc. Praxis Precision Medicines Reports $303.3 Million Net Loss for 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Praxis Precision Medicines, Inc. Praxis Precision Medicines Reports $73.9 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Praxis Precision Medicines, Inc. Praxis Precision Medicines Reports $71.1 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Praxis Precision Medicines, Inc. Praxis Precision Medicines Reports $69.3 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Praxis Precision Medicines, Inc. Praxis Precision Medicines Reports $182.8 Million Net Loss for 2024, Highlights Funding and Clinical Developments

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Praxis Precision Medicines, Inc. Praxis Precision Medicines Reports Significant Financial Developments, Increased Cash Reserves, and Ongoing Operating Losses

Via official filing (AI summary) | over 1 year ago | 0 comments